Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Schering-Plough/Aveo Will Develop Novel Cancer Biologic Based On Biomarkers

This article was originally published in The Pink Sheet Daily

Executive Summary

Schering gains access to preclinical antibody, as well as biomarker profiling technology in deal worth up to $477.5 million

You may also be interested in...



Japan's Kirin, Kyowa Merge To Strengthen Biotechnology Focus

Kirin Holdings and Kyowa Hakko will seek to bring together each company's strength in biotech to create a global research and development-centered Japanese drug company. The two Tokyo-based companies announced a merger agreement Oct. 22, reflecting the ongoing consolidation of the Japanese drug industry

Japan’s Kirin, Kyowa Merge To Strengthen Biotechnology Focus

Kirin will acquire a 50.1 percent stake in Kyowa Hakko in a deal valued at close to ¥300 billion ($2.64 billion).

Japan’s Kirin, Kyowa Merge To Strengthen Biotechnology Focus

Kirin will acquire a 50.1 percent stake in Kyowa Hakko in a deal valued at close to ¥300 billion ($2.64 billion).

Topics

UsernamePublicRestriction

Register

OM007016

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel